



8 June 2021

**Proteome Sciences plc
("Proteome Sciences" or the "Company")**

Grant of Options and PDMR/director shareholdings

Proteome Sciences announces the grant of options over new ordinary shares of 1p each in the Company ("Ordinary Shares") under the Company's share option schemes ("Options"). A total of 14,000,000 Options have today been issued to three directors of the Company.

Details of the Options granted to directors are outlined in the table below:

Name of Director	Number of Options Granted	Total number of options now held
Dr Mariola Soehngen	9,000,000	9,000,000
Dr Ian Pike	2,500,000	2,500,000
Mr Richard Dennis	2,500,000	2,500,000

The Options are exercisable at the Ordinary Shares' nominal value of 1p per Option. For Dr Mariola Soehngen these Options will vest in three equal annual tranches on 15 September 2021, 2022 and 2023. For Dr Ian Pike and Mr Richard Dennis, the Options will vest in three tranches as to 1,000,000 on 15 September 2021 and 2022 and 500,000 on 15 September 2023. Each Option is exercisable into one Ordinary Share and once vested, can be exercised up until the 10th anniversary of today's date.

The Options granted today represent approximately 4.7 per cent of the Company's current issued share capital. In total 15,124,000 Options are now outstanding, representing approximately 5.1 per cent of the Company's current issued share capital.

Further details and the information required in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014 are set out at the end of this announcement.

For further information:

Proteome Sciences plc

Dr Mariola Soehngen, Chief Executive Officer
Dr Ian Pike, Chief Scientific Officer

Tel: +44 (0)20 7043 2116

Allenby Capital Limited (AIM Nominated Adviser & Broker)

John Depasquale / Jeremy Porter

Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods

for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

The below notification is made in accordance with the requirements of the UK Market Abuse Regulation.

1.	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name:	Mariola Soehngen				
2.	Reason for the notification					
a)	Position/status:	Chief Executive Officer				
b)	Initial notification/Amendment:	Initial Notification				
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name:	Proteome Sciences Plc				
b)	LEI:	213800Q62ICXANKU2986				
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument: Identification code:	Ordinary Shares of 1p nominal value GB0003104196				
b)	Nature of the transaction:	Grant of options under the Proteome Sciences plc 2011 Long Term Share Incentive Plan to acquire ordinary shares of 1p each in Proteome Sciences plc				
c)	Price(s) and volume(s):	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>0.01</td> <td>9,000,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	0.01	9,000,000
Price(s)	Volume(s)					
0.01	9,000,000					
d)	Aggregated information:	Single transaction as in c) above				

	<ul style="list-style-type: none"> Aggregated volume: Price:	Average Price	Volume(s)
		Exercisable at nominal price of 1p per share	9,000,000
e)	Date of the transaction:	8 June 2021	
f)	Place of the transaction:	N/A	

1.	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name:	Ian Pike	
2.	Reason for the notification		
a)	Position/status:	Chief Scientific Officer	
b)	Initial notification/Amendment:	Initial Notification	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name:	Proteome Sciences Plc	
b)	LEI:	213800Q62ICXANKU2986	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument: Identification code:	Ordinary Shares of 1p nominal value GB0003104196	
b)	Nature of the transaction:	Grant of options under the Proteome Sciences plc 2011 Long Term Share Incentive Plan to acquire ordinary shares of 1p each in Proteome Sciences plc	
c)	Price(s) and volume(s):	Price(s)	Volume(s)
		0.01	2,500,000
d)	Aggregated information: <ul style="list-style-type: none"> Aggregated volume: 	Single transaction as in c) above	
		Average Price	Volume(s)

	<ul style="list-style-type: none"> Price: 	Exercisable at nominal price of 1p per share	2,500,000
e)	Date of the transaction:	8 June 2021	
f)	Place of the transaction:	N/A	

1.	Details of the person discharging managerial responsibilities/person closely associated						
a)	Name:	Richard Dennis					
2.	Reason for the notification						
a)	Position/status:	Chief Commercial Officer					
b)	Initial notification/Amendment:	Initial Notification					
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name:	Proteome Sciences Plc					
b)	LEI:	213800Q62ICXANKU2986					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument: Identification code:	Ordinary Shares of 1p nominal value GB0003104196					
b)	Nature of the transaction:	Grant of options under the Proteome Sciences plc 2011 Long Term Share Incentive Plan to acquire ordinary shares of 1p each in Proteome Sciences plc					
c)	Price(s) and volume(s):	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercisable at nominal price of 1p per share</td> <td>2,500,000</td> </tr> </tbody> </table>		Price(s)	Volume(s)	Exercisable at nominal price of 1p per share	2,500,000
Price(s)	Volume(s)						
Exercisable at nominal price of 1p per share	2,500,000						
d)	Aggregated information: <ul style="list-style-type: none"> Aggregated volume: 	Single transaction as in c) above <table border="1"> <thead> <tr> <th>Average Price</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> </tr> </tbody> </table>		Average Price	Volume(s)		
Average Price	Volume(s)						

	Price:	Exercisable at nominal price of 1p per share	2,500,000
e)	Date of the transaction:	8 June 2021	
f)	Place of the transaction:	N/A	